CPT® Code 91319

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

The CPT® Code 91319 refers to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, specifically designed to combat coronavirus disease (COVID-19). This vaccine utilizes a formulation of messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), which is a method that allows the mRNA to be effectively delivered into human cells. The dosage of this vaccine is 10 mcg per 0.3 mL, and it is intended for intramuscular use. The mRNA contained in the vaccine corresponds to the spike protein of the coronavirus, which is a critical component that the virus uses to enter human cells. Upon administration, the cells utilize the mRNA as a template to produce the spike protein, which is then recognized by the immune system as a foreign entity. This recognition triggers an immune response, leading to the production of antibodies that can protect the individual from future infections with the virus. This specific vaccine formulation is a monovalent component that targets the XBB.1.5 Omicron variant of the virus, making it particularly relevant for current strains. The vaccine is designed for pediatric use, specifically for children aged 5 to 11 years, and is reported as a supply code, meaning it covers the vaccine itself but does not include the administration of the vaccine, which is billed separately. The tris-sucrose formulation is noteworthy as it includes buffering agents that help stabilize the vaccine, maintaining its pH balance and allowing for storage at standard refrigerator temperatures, which is essential for ensuring the vaccine's efficacy and safety prior to administration.